Small
molecule
drug
design
hinges
on
obtaining
co-crystallized
ligand-protein
structures.
Despite
AlphaFold2’s
strides
in
protein
native
structure
prediction,
its
focus
apo
structures
overlooks
ligands
and
associated
holo
Moreover,
designing
selective
drugs
often
benefits
from
the
targeting
of
diverse
metastable
conformations.
Therefore,
direct
application
AlphaFold2
models
virtual
screening
dis-covery
remains
tentative.
Here,
we
demonstrate
an
based
framework
combined
with
all-atom
enhanced
sampling
molecular
dynamics
induced
fit
docking,
named
AF2RAVE-Glide,
to
conduct
computational
model
small
binding
kinase
conformations,
initiated
sequences.
We
AF2RAVE-Glide
workflow
three
different
kinases
their
type
I
II
inhibitors,
special
emphasis
known
inhibitors
which
target
classical
DFG-out
state.
These
states
are
not
easy
sample
AlphaFold2.
Here
how
AF2RAVE
these
conformations
can
be
sampled
for
high
enough
ac-
curacy
enable
subsequent
docking
more
than
50%
success
rates
across
calculations.
believe
protocol
should
deployable
other
proteins
generally.
Deep-learning
methods
have
revolutionized
protein
structure
prediction
and
design
but
are
presently
limited
to
protein-only
systems.
We
describe
RoseTTAFold
All-Atom
(RFAA),
which
combines
a
residue-based
representation
of
amino
acids
DNA
bases
with
an
atomic
all
other
groups
model
assemblies
that
contain
proteins,
nucleic
acids,
small
molecules,
metals,
covalent
modifications,
given
their
sequences
chemical
structures.
By
fine-tuning
on
denoising
tasks,
we
developed
RFdiffusion
(RFdiffusionAA),
builds
structures
around
molecules.
Starting
from
random
distributions
acid
residues
surrounding
target
designed
experimentally
validated,
through
crystallography
binding
measurements,
proteins
bind
the
cardiac
disease
therapeutic
digoxigenin,
enzymatic
cofactor
heme,
light-harvesting
molecule
bilin.
Proceedings of the National Academy of Sciences,
Год журнала:
2023,
Номер
120(44)
Опубликована: Окт. 25, 2023
The
AlphaFold
Protein
Structure
Database
contains
predicted
structures
for
millions
of
proteins.
For
the
majority
human
proteins
that
contain
intrinsically
disordered
regions
(IDRs),
which
do
not
adopt
a
stable
structure,
it
is
generally
assumed
these
have
low
AlphaFold2
confidence
scores
reflect
low-confidence
structural
predictions.
Here,
we
show
assigns
confident
to
nearly
15%
IDRs.
By
comparison
experimental
NMR
data
subset
IDRs
are
known
conditionally
fold
(i.e.,
upon
binding
or
under
other
specific
conditions),
find
often
predicts
structure
folded
state.
Based
on
databases
fold,
estimate
can
identify
folding
at
precision
as
high
88%
10%
false
positive
rate,
remarkable
considering
IDR
were
minimally
represented
in
its
training
data.
We
disease
mutations
fivefold
enriched
over
general
and
up
80%
prokaryotes
compared
less
than
20%
eukaryotic
These
results
indicate
large
proteomes
eukaryotes
function
absence
conditional
folding,
but
acquire
folds
more
sensitive
mutations.
emphasize
predictions
reveal
functionally
relevant
plasticity
within
cannot
offer
realistic
ensemble
representations
Annual Review of Biochemistry,
Год журнала:
2024,
Номер
93(1), С. 389 - 410
Опубликована: Апрель 10, 2024
Molecular
docking
has
become
an
essential
part
of
a
structural
biologist's
and
medicinal
chemist's
toolkits.
Given
chemical
compound
the
three-dimensional
structure
molecular
target—for
example,
protein—docking
methods
fit
into
target,
predicting
compound's
bound
binding
energy.
Docking
can
be
used
to
discover
novel
ligands
for
target
by
screening
large
virtual
libraries.
also
provide
useful
starting
point
structure-based
ligand
optimization
or
investigating
ligand's
mechanism
action.
Advances
in
computational
methods,
including
both
physics-based
machine
learning
approaches,
as
well
complementary
experimental
techniques,
are
making
even
more
powerful
tool.
We
review
how
works
it
drive
drug
discovery
biological
research.
describe
its
current
limitations
ongoing
efforts
overcome
them.
bioRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2023,
Номер
unknown
Опубликована: Окт. 9, 2023
Abstract
Although
AlphaFold2
(AF2)
and
RoseTTAFold
(RF)
have
transformed
structural
biology
by
enabling
high-accuracy
protein
structure
modeling,
they
are
unable
to
model
covalent
modifications
or
interactions
with
small
molecules
other
non-protein
that
can
play
key
roles
in
biological
function.
Here,
we
describe
All-Atom
(RFAA),
a
deep
network
capable
of
modeling
full
assemblies
containing
proteins,
nucleic
acids,
molecules,
metals,
given
the
sequences
polymers
atomic
bonded
geometry
modifications.
Following
training
on
structures
Protein
Data
Bank
(PDB),
RFAA
has
comparable
prediction
accuracy
AF2,
excellent
performance
CAMEO
for
flexible
backbone
molecule
docking,
reasonable
proteins
multiple
acid
chains
which,
our
knowledge,
no
existing
method
simultaneously.
By
fine-tuning
diffusive
denoising
tasks,
develop
RFdiffusion
(RFdiffusionAA
)
,
which
generates
binding
pockets
directly
building
around
molecules.
Starting
from
random
distributions
amino
residues
surrounding
target
design
experimentally
validate
bind
cardiac
disease
therapeutic
digoxigenin,
enzymatic
cofactor
heme,
optically
active
bilin
potential
expanding
range
wavelengths
captured
photosynthesis.
We
anticipate
RFdiffusionAA
will
be
widely
useful
designing
complex
biomolecular
systems.
Journal of Chemical Information and Modeling,
Год журнала:
2023,
Номер
63(6), С. 1668 - 1674
Опубликована: Март 9, 2023
Machine
learning-based
protein
structure
prediction
algorithms,
such
as
RosettaFold
and
AlphaFold2,
have
greatly
impacted
the
structural
biology
field,
arousing
a
fair
amount
of
discussion
around
their
potential
role
in
drug
discovery.
While
there
are
few
preliminary
studies
addressing
usage
these
models
virtual
screening,
none
them
focus
on
prospect
hit-finding
real-world
screen
with
model
based
low
prior
information.
In
order
to
address
this,
we
developed
an
AlphaFold2
version
where
exclude
all
templates
more
than
30%
sequence
identity
from
model-building
process.
previous
study,
used
those
conjunction
state-of-the-art
free
energy
perturbation
methods
demonstrated
that
it
is
possible
obtain
quantitatively
accurate
results.
this
work,
using
structures
rigid
receptor-ligand
docking
studies.
Our
results
indicate
out-of-the-box
Alphafold2
not
ideal
scenario
for
screening
campaigns;
fact,
strongly
recommend
include
some
post-processing
modeling
drive
binding
site
into
realistic
holo
model.
AlphaFold2
(AF2)
models
have
had
wide
impact
but
mixed
success
in
retrospective
ligand
recognition.
We
prospectively
docked
large
libraries
against
unrefined
AF2
of
the
σ
Drug Discovery Today,
Год журнала:
2023,
Номер
28(6), С. 103551 - 103551
Опубликована: Март 11, 2023
Drug
discovery
is
arguably
a
highly
challenging
and
significant
interdisciplinary
aim.
The
stunning
success
of
the
artificial
intelligence-powered
AlphaFold,
whose
latest
version
buttressed
by
an
innovative
machine-learning
approach
that
integrates
physical
biological
knowledge
about
protein
structures,
raised
drug
hopes
unsurprisingly,
have
not
come
to
bear.
Even
though
accurate,
models
are
rigid,
including
pockets.
AlphaFold's
mixed
performance
poses
question
how
its
power
can
be
harnessed
in
discovery.
Here
we
discuss
possible
ways
going
forward
wielding
strengths,
while
bearing
mind
what
AlphaFold
cannot
do.
For
kinases
receptors,
input
enriched
active
(ON)
state
better
chance
rational
design
success.
AlphaFold2
is
a
promising
new
tool
for
researchers
to
predict
protein
structures
and
generate
high-quality
models,
with
low
backbone
global
root-mean-square
deviation
(RMSD)
when
compared
experimental
structures.
However,
it
unclear
if
the
predicted
by
will
be
valuable
targets
of
docking.
To
address
this
question,
we
redocked
ligands
in
PDBbind
datasets
against
co-crystallized
receptor
using
AutoDock-GPU.
We
find
that
quality
measure
provided
during
structure
prediction
not
good
predictor
docking
performance,
despite
accurately
reflecting
alpha
carbon
alignment
Removing
low-confidence
regions
making
side
chains
flexible
improves
outcomes.
Overall,
conformation,
fine
structural
details
limit
naive
application
models
as
targets.
Molecular
dynamics
(MD)
simulations
and
computer-aided
drug
design
(CADD)
have
advanced
substantially
over
the
past
two
decades,
thanks
to
continuous
computer
hardware
software
improvements.
Given
these
advancements,
MD
are
poised
become
even
more
powerful
tools
for
investigating
dynamic
interactions
between
potential
small-molecule
drugs
their
target
proteins,
with
significant
implications
pharmacological
research.